A detailed history of Capital International Investors transactions in Amgen Inc stock. As of the latest transaction made, Capital International Investors holds 8,716,562 shares of AMGN stock, worth $2.51 Billion. This represents 0.56% of its overall portfolio holdings.

Number of Shares
8,716,562
Previous 8,378,960 4.03%
Holding current value
$2.51 Billion
Previous $2.62 Billion 7.28%
% of portfolio
0.56%
Previous 0.55%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$309.38 - $337.38 $104 Million - $114 Million
337,602 Added 4.03%
8,716,562 $2.81 Billion
Q2 2024

Aug 13, 2024

BUY
$262.75 - $319.31 $361 Million - $439 Million
1,373,691 Added 19.61%
8,378,960 $2.62 Billion
Q1 2024

May 14, 2024

BUY
$268.87 - $324.56 $1.59 Billion - $1.92 Billion
5,923,915 Added 547.82%
7,005,269 $1.99 Billion
Q4 2023

Feb 13, 2024

BUY
$255.7 - $288.46 $86.6 Million - $97.6 Million
338,515 Added 45.57%
1,081,354 $311 Million
Q3 2023

Nov 13, 2023

BUY
$218.65 - $271.46 $35.9 Million - $44.6 Million
164,374 Added 28.42%
742,839 $200 Million
Q2 2023

Aug 11, 2023

BUY
$214.27 - $253.37 $23,355 - $27,617
109 Added 0.02%
578,465 $128 Million
Q1 2023

May 15, 2023

BUY
$225.79 - $275.2 $41,093 - $50,086
182 Added 0.03%
578,356 $140 Million
Q4 2022

Feb 14, 2023

BUY
$229.03 - $291.01 $57,257 - $72,752
250 Added 0.04%
578,174 $152 Million
Q3 2022

Nov 14, 2022

BUY
$224.46 - $253.15 $16,610 - $18,733
74 Added 0.01%
577,924 $130 Million
Q2 2022

Aug 15, 2022

SELL
$230.71 - $256.74 $13.2 Million - $14.7 Million
-57,138 Reduced 9.0%
577,850 $141 Million
Q1 2022

May 16, 2022

SELL
$219.27 - $242.57 $429 Million - $474 Million
-1,954,872 Reduced 75.48%
634,988 $154 Million
Q4 2021

Feb 14, 2022

BUY
$198.88 - $227.6 $46,736 - $53,486
235 Added 0.01%
2,589,860 $583 Million
Q3 2021

Nov 15, 2021

BUY
$212.27 - $248.7 $91.4 Million - $107 Million
430,393 Added 19.93%
2,589,625 $551 Million
Q2 2021

Aug 16, 2021

BUY
$233.58 - $259.14 $44.3 Million - $49.2 Million
189,782 Added 9.64%
2,159,232 $526 Million
Q1 2021

May 14, 2021

SELL
$221.91 - $258.6 $82.4 Million - $96 Million
-371,136 Reduced 15.86%
1,969,450 $490 Million
Q4 2020

Feb 12, 2021

SELL
$216.38 - $257.67 $164 Million - $196 Million
-759,446 Reduced 24.5%
2,340,586 $538 Million
Q3 2020

Nov 13, 2020

SELL
$234.65 - $260.95 $237 Million - $264 Million
-1,010,388 Reduced 24.58%
3,100,032 $788 Million
Q2 2020

Aug 14, 2020

SELL
$197.81 - $242.74 $315 Million - $386 Million
-1,589,967 Reduced 27.89%
4,110,420 $969 Million
Q1 2020

May 15, 2020

BUY
$182.24 - $241.7 $170 Million - $226 Million
933,191 Added 19.58%
5,700,387 $1.16 Billion
Q4 2019

Feb 18, 2020

SELL
$189.21 - $243.2 $49.2 Million - $63.3 Million
-260,127 Reduced 5.17%
4,767,196 $1.15 Billion
Q3 2019

Nov 14, 2019

SELL
$174.11 - $208.62 $692 Million - $829 Million
-3,972,062 Reduced 44.14%
5,027,323 $973 Million
Q2 2019

Aug 14, 2019

BUY
$166.7 - $195.41 $6.55 Million - $7.68 Million
39,282 Added 0.44%
8,999,385 $1.66 Billion
Q1 2019

May 15, 2019

SELL
$180.87 - $203.88 $298 Million - $336 Million
-1,646,336 Reduced 15.52%
8,960,103 $1.7 Billion
Q4 2018

Feb 14, 2019

SELL
$178.4 - $208.25 $86.8 Million - $101 Million
-486,743 Reduced 4.39%
10,606,439 $2.06 Billion
Q3 2018

Nov 14, 2018

BUY
$185.29 - $208.89 $1.54 Billion - $1.74 Billion
8,329,861 Added 301.44%
11,093,182 $2.3 Billion
Q2 2018

Aug 14, 2018

BUY
$166.05 - $186.51 $12,121 - $13,615
73 Added 0.0%
2,763,321 $510 Million
Q1 2018

May 15, 2018

BUY
$169.43 - $198.0 $14.1 Million - $16.5 Million
83,200 Added 3.1%
2,763,248 $471 Million
Q3 2017

Nov 14, 2017

BUY
$167.29 - $191.0 $448 Million - $512 Million
2,680,048
2,680,048 $500 Million

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $154B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Capital International Investors Portfolio

Follow Capital International Investors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital International Investors, based on Form 13F filings with the SEC.

News

Stay updated on Capital International Investors with notifications on news.